Baxter International Inc;Baxter Healthcare S.A.;University of Pittsburgh of the Commonwealth System of Higher Education
发明人:
申请号：
EP13175410.3
公开号：
EP2647712A3
申请日:
2007.08.06
申请国别(地区):
EP
年份:
2013
代理人:
摘要：
AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to reverse an autoimmune diabetes condition in NOD mice in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations.
